Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breakfree-SLE
NCT07015983Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 16
01
Overview
A Phase 2 trial of BMS-986353 in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by Bristol Myers Squibb. Started Jul 2025; status: active, not recruiting.
02
Drugs
BMS-986353
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07015983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015983.